Literature DB >> 3764686

The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients.

J P Crowe, N H Gordon, C A Hubay, O H Pearson, J S Marshall, W L McGuire.   

Abstract

As part of a multi-institutional breast cancer data base, 501 stage I, node negative patients have been followed prospectively with a median of 89 months. Patients were treated by a modified radical mastectomy without postoperative therapy. Estrogen receptor (ER) content of the primary tumor was determined in all cases. For the entire patient group at 10 years, the disease-free survival (DFS) rate is 72% and the overall survival (OS) rate is 85%. Both ER value and race (black versus white) were found to be significant prognostic variables for DFS (p = 0.008 and 0.02, respectively) and for OS (p = 0.0001 and 0.01, respectively). ER positive patients had a better DFS and OS rate compared with ER negative patients (74% versus 66% and 90% versus 68%, respectively). Black patients had significantly worse DFS and OS rates compared with white patients (64% versus 74% and 75% versus 86%, respectively). Statistical interaction between the ER and race variables was apparent when comparing the similar DFS for ER positive white (75%), ER negative white (72%), and ER positive black (73%) patients in contrast to a DFS of less than 42% at 10 years for the ER negative black patients. An analysis of the data for the ER negative black patients suggested that the postmenopausal ER negative black patients are at particularly high risk of recurrence and death from breast cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3764686

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions.

Authors:  Nancy Krieger; Jarvis T Chen; James H Ware; Afamia Kaddour
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

2.  Breast cancer risk factors in African-American women: the Howard University Tumor Registry experience.

Authors:  A E Laing; F M Demenais; R Williams; G Kissling; V W Chen; G E Bonney
Journal:  J Natl Med Assoc       Date:  1993-12       Impact factor: 1.798

3.  Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality.

Authors:  Emily Rose Smith; Swann Arp Adams; Irene Prabhu Das; Matteo Bottai; Jeanette Fulton; James R Hebert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10-03       Impact factor: 4.254

Review 4.  The prognostic significance of race and survival from breast cancer: a model for assessing the reliability of reported survival differences.

Authors:  M Roach; M Alexander
Journal:  J Natl Med Assoc       Date:  1995-03       Impact factor: 1.798

Review 5.  How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.

Authors:  Diana P Saraiva; M Guadalupe Cabral; António Jacinto; Sofia Braga
Journal:  ESMO Open       Date:  2017-09-14

6.  ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.

Authors:  Anieta M Sieuwerts; Márcia A Inda; Marcel Smid; Henk van Ooijen; Anja van de Stolpe; John W M Martens; Wim F J Verhaegh
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.